SpaceX is sitting on $100 billion in cash but may need another $100 billion in debt — and bond markets are lining up to give it to them at investment-grade rates.
Bloomberg Intelligence
SpaceX is sitting on $100 billion in cash but may need another $100 billion in debt — and bond markets are lining up to give it to them at investment-grade rates.
TL;DR
Carnival Cruise stock dropped 5% after guidance was cut due to Middle East conflict raising fuel and airfare costs, though the fleet remains 93% booked [1] — Brian Egger "93% booked for 2025: Carnival Cruise Lines reported it is 93% booked for the current year despite macro uncertainty and Middle East conflic…" 03:18 . SpaceX launches its inaugural investment-grade bond offering — analysts expect massive demand, with bonds priced wide to peers, making it attractive despite negative free cash flow [2] — Robert Schiffman "SpaceX's first-ever investment-grade bond offering will attract heavy demand for one simple reason: nobody owns it yet. Bonds priced wide t…" 11:04 . Google loses key AI talent to Anthropic, now seen as the frontier model leader [3] — Mandeep Singh "Google market cap dropped $250B: Google's market cap fell by approximately $250 billion following the departure of key AI talent to competi…" 20:50 . Eli Lilly's CEO Dave Ricks transformed the 150-year-old pharma giant into the world's most valuable healthcare company by slashing drug development timelines from 14 years to 5 with GLP-1 drugs.
Bloomberg Intelligence analysts cover Carnival Cruise earnings, SpaceX's bond debut, Google's AI talent exodus, and Eli Lilly's GLP-1 strategy.
Opening sponsor reads for Brookfield Asset Management and IBM's AI business integration messaging.
Windows 11 Pro security stats sponsor read, followed by the Bloomberg Intelligence Podcast introduction and setup.
Brian Egger breaks down Carnival's 5% stock drop, 100 bps guidance cut since March, 93% booking rate, capacity discipline, and Viking Cruises' luxury outperformance. [1] — Brian Egger "93% booked for 2025: Carnival Cruise Lines reported it is 93% booked for the current year despite macro uncertainty and Middle East conflic…" 03:18 [2] — Brian Egger "Carnival supply growth: 0.9% in 2026: Carnival is growing capacity by only about 1% in 2026, far below the industry average of mid-single-d…" 05:06
Brian Egger briefly notes Las Vegas is stabilizing, with better pricing and visitation after a tougher 2025 marked by event comparison headwinds and midweek leisure pressure.
Mid-episode sponsor reads for Brookfield, IBM, and Public.com's AI-powered portfolio automation platform.
Scarlet Fu sets up SpaceX's 22% three-day post-IPO drop and its simultaneous inaugural investment-grade bond sale to refinance a bridge loan and fund AI buildout. [1] — Scarlet Fu "SpaceX 3-day post-IPO drop: ~22%: SpaceX stock fell approximately 22% over three days following its IPO, reflecting a repricing of initial …" 10:00
Senior credit analyst Robert Schiffman explains why bond markets will flock to SpaceX's debut, citing scarcity, wide pricing vs BBB peers, $100B cash, and comparing Musk to Buffett. [1] — Robert Schiffman "SpaceX's first-ever investment-grade bond offering will attract heavy demand for one simple reason: nobody owns it yet. Bonds priced wide t…" 11:04 [2] — Robert Schiffman "Credit markets aren't scared of the Elon factor — they see it as a reward. Robert Schiffman argues Musk is to this generation what Buffett …" 14:00
Repeat sponsor reads for Public.com's AI agent portfolio platform and Venture Global's US energy infrastructure message.
Mandeep Singh evaluates SpaceX's post-IPO shakeout, noting orbital data center excitement faded, bond and equity issuance for Cursor acquisition adds 3% dilution, and it's not a cash flow story.
Mandeep Singh argues Anthropic is now the frontier AI leader, Google's $250B market cap drop reflects talent loss panic, and the Cursor acquisition was essential to SpaceX staying above $100. [1] — Mandeep Singh "Google's AI crown has been stolen. Anthropic's latest Mythos model has the government blocking access because it's too capable. Google has …" 20:50 [2] — Mandeep Singh "The Cursor acquisition wasn't just about coding tools — it was a talent and narrative lifeline. Mandeep Singh argues SpaceX stock would hav…" 21:58
Third block of sponsor reads: Public.com AI agents, Venture Global US energy, and 4imprint promotional products.
Madison Muller recounts Eli Lilly's history, its dry spell, and how GLP-1 weight loss drugs transformed it into the world's most valuable healthcare company under CEO Dave Ricks. [1] — Madison Muller "Eli Lilly had a dry spell bad enough to tank its stock and trigger CEO turnover. Then weight loss drugs arrived and transformed it into the…" 27:05
Madison Muller details how CEO Dave Ricks made speed Eli Lilly's number-one priority, cutting drug development from 13–14 years to 5, and piloted this approach with tirzepatide. [1] — Madison Muller "When Dave Ricks took over as CEO, Eli Lilly was one of the slowest drug developers in the industry. He mandated speed above all else. The r…" 28:38
Madison Muller explains Lilly's strategy to survive patent expiry: deploying GLP-1 windfall into internal R&D, record acquisitions, and AI via an NVIDIA partnership and on-site supercomputer. [1] — Madison Muller "Eli Lilly is deploying its GLP-1 windfall into internal R&D, acquisitions, and AI — including a partnership with NVIDIA and an on-site supe…" 31:40
Bloomberg Intelligence Podcast outro with show information, closing Windows 11 Pro sponsor read, Michigan business development promo, and Venture Global ad.
Chapter 2 · 01:35
Windows 11 Pro security stats sponsor read, followed by the Bloomberg Intelligence Podcast introduction and setup.
Carnival's full-year revenue yield growth guidance was cut 100 basis points since March. The culprit: higher airfare and fuel costs, disrupted Eastern Mediterranean itineraries, and a war that lasted longer than anyone expected.
Carnival's full-year revenue yield growth guidance was reduced by 100 basis points since March 2025, driven by higher airfare, gas prices, and Middle East conflict disruptions.
Chapter 3 · 02:50
Brian Egger breaks down Carnival's 5% stock drop, 100 bps guidance cut since March, 93% booking rate, capacity discipline, and Viking Cruises' luxury outperformance. [1] — Brian Egger "93% booked for 2025: Carnival Cruise Lines reported it is 93% booked for the current year despite macro uncertainty and Middle East conflic…" 03:18 [2] — Brian Egger "Carnival supply growth: 0.9% in 2026: Carnival is growing capacity by only about 1% in 2026, far below the industry average of mid-single-d…" 05:06
Despite geopolitical headwinds, Carnival is 93% booked for the year and posting positive yield growth. The cruise industry is proving more resilient than the macro environment might suggest.
Carnival Cruise Lines reported it is 93% booked for the current year despite macro uncertainty and Middle East conflict disruptions.
While the cruise industry adds capacity at mid-single-digit rates, Carnival is growing supply by just 0.9% in 2026 — a deliberately measured approach that looks smart given today's environment.
Carnival is growing capacity by only about 1% in 2026, far below the industry average of mid-single-digit supply growth, reflecting a measured approach.
The broader cruise industry is adding capacity at a mid-single-digit rate annually, even as Carnival takes a more conservative approach.
Viking Cruise stock has surged 40% year-to-date and doubled over the past 12 months, outperforming broader cruise sector peers.
Chapter 5 · 07:40
Mid-episode sponsor reads for Brookfield, IBM, and Public.com's AI-powered portfolio automation platform.
SpaceX stock fell 22% in three days after its IPO as early investors flushed out positions. The market is now asking a hard question: who actually wants to own this stock for the long term when it's not a cash flow story?
SpaceX stock fell approximately 22% over three days following its IPO, reflecting a repricing of initial euphoria as the market sought long-term holders.
Chapter 7 · 11:04
Senior credit analyst Robert Schiffman explains why bond markets will flock to SpaceX's debut, citing scarcity, wide pricing vs BBB peers, $100B cash, and comparing Musk to Buffett. [1] — Robert Schiffman "SpaceX's first-ever investment-grade bond offering will attract heavy demand for one simple reason: nobody owns it yet. Bonds priced wide t…" 11:04 [2] — Robert Schiffman "Credit markets aren't scared of the Elon factor — they see it as a reward. Robert Schiffman argues Musk is to this generation what Buffett …" 14:00
SpaceX's first-ever investment-grade bond offering will attract heavy demand for one simple reason: nobody owns it yet. Bonds priced wide to BBB peers makes it a screaming buy for credit investors hungry for AI-linked diversification.
SpaceX sits on $100 billion in cash, is committed to investment-grade ratings, and has a liquidity profile that can sustain its burn rate for 3–4 years. That's why the ratings agencies didn't flinch.
SpaceX raised approximately $85 billion in equity through its IPO and may need an additional $100 billion in debt for its AI and space buildout.
SpaceX is sitting on $100 billion in cash, and its liquidity profile is considered strong enough to sustain 3–4 years of capital burn.
Credit markets aren't scared of the Elon factor — they see it as a reward. Robert Schiffman argues Musk is to this generation what Buffett was to the last one: a rare value creator whose vision deserves a premium.
SpaceX carries a $2 trillion equity market capitalization, reflecting immense investor enthusiasm for Elon Musk's AI and space vision.
Chapter 9 · 19:00
Mandeep Singh evaluates SpaceX's post-IPO shakeout, noting orbital data center excitement faded, bond and equity issuance for Cursor acquisition adds 3% dilution, and it's not a cash flow story.
Chapter 10 · 20:45
Mandeep Singh argues Anthropic is now the frontier AI leader, Google's $250B market cap drop reflects talent loss panic, and the Cursor acquisition was essential to SpaceX staying above $100. [1] — Mandeep Singh "Google's AI crown has been stolen. Anthropic's latest Mythos model has the government blocking access because it's too capable. Google has …" 20:50 [2] — Mandeep Singh "The Cursor acquisition wasn't just about coding tools — it was a talent and narrative lifeline. Mandeep Singh argues SpaceX stock would hav…" 21:58
Google's AI crown has been stolen. Anthropic's latest Mythos model has the government blocking access because it's too capable. Google has no equivalent, no timeline, and is hemorrhaging top researchers.
Google's market cap fell by approximately $250 billion following the departure of key AI talent to competitors like Anthropic.
The Cursor acquisition wasn't just about coding tools — it was a talent and narrative lifeline. Mandeep Singh argues SpaceX stock would have fallen below $100 without it, as the deal gave the company its most credible AI use case.
Chapter 12 · 26:20
Madison Muller recounts Eli Lilly's history, its dry spell, and how GLP-1 weight loss drugs transformed it into the world's most valuable healthcare company under CEO Dave Ricks. [1] — Madison Muller "Eli Lilly had a dry spell bad enough to tank its stock and trigger CEO turnover. Then weight loss drugs arrived and transformed it into the…" 27:05
Eli Lilly had a dry spell bad enough to tank its stock and trigger CEO turnover. Then weight loss drugs arrived and transformed it into the world's most valuable healthcare company. The comeback story of the decade in pharma.
Eli Lilly, founded 150 years ago, is now the most valuable healthcare company in the world, transformed by the success of its GLP-1 weight loss drugs.
Chapter 13 · 28:38
Madison Muller details how CEO Dave Ricks made speed Eli Lilly's number-one priority, cutting drug development from 13–14 years to 5, and piloted this approach with tirzepatide. [1] — Madison Muller "When Dave Ricks took over as CEO, Eli Lilly was one of the slowest drug developers in the industry. He mandated speed above all else. The r…" 28:38
When Dave Ricks took over as CEO, Eli Lilly was one of the slowest drug developers in the industry. He mandated speed above all else. The result: tirzepatide went from lab to approval in about 5 years — less than half the old timeline.
Under CEO Dave Ricks, Eli Lilly cut drug development timelines from 13–14 years to around 5 years, exemplified by the speedy development of tirzepatide (Mounjaro/Zepbound).
Chapter 14 · 31:40
Madison Muller explains Lilly's strategy to survive patent expiry: deploying GLP-1 windfall into internal R&D, record acquisitions, and AI via an NVIDIA partnership and on-site supercomputer. [1] — Madison Muller "Eli Lilly is deploying its GLP-1 windfall into internal R&D, acquisitions, and AI — including a partnership with NVIDIA and an on-site supe…" 31:40
Eli Lilly is deploying its GLP-1 windfall into internal R&D, acquisitions, and AI — including a partnership with NVIDIA and an on-site supercomputer. The question is whether AI can actually deliver new drugs before Lilly's patents expire.
No indexed bits in this chapter.
Credit markets aren't scared of the Elon factor — they see it as a reward. Robert Schiffman argues Musk is to this generation what Buffett was to the last one: a rare value creator whose vision deserves a premium.
Google's AI crown has been stolen. Anthropic's latest Mythos model has the government blocking access because it's too capable. Google has no equivalent, no timeline, and is hemorrhaging top researchers.
When Dave Ricks took over as CEO, Eli Lilly was one of the slowest drug developers in the industry. He mandated speed above all else. The result: tirzepatide went from lab to approval in about 5 years — less than half the old timeline.
This episode
Factual claims made this episode, and whether a source was named.
Carnival's full-year constant-currency revenue yield growth guidance was reduced by 100 basis points since March 2025.
Carnival Cruise Lines is approximately 93% booked for fiscal year 2025.
Carnival is growing cruise capacity by only approximately 0.9% in 2026, well below the industry-wide mid-single-digit supply growth rate.
Viking Cruises stock is up approximately 40% year-to-date and has doubled over the last 12 months.
SpaceX stock fell approximately 22% over three days following its IPO.
SpaceX raised approximately $85–86 billion in equity through its IPO.
SpaceX is sitting on $100 billion in cash and has a burn rate that would take 3–4 years to exhaust its current capital.
SpaceX's negative free cash flow is projected to be $20–40 billion annually.
SpaceX carries a $2 trillion equity market capitalization.
Google's market cap dropped by approximately $250 billion following the departure of key AI talent.
Eli Lilly is now the most valuable healthcare company in the world.
Eli Lilly previously took 13 to 14 years to bring a drug from lab to approval, but reduced this to around 5 years under CEO Dave Ricks.
Teams using Windows 11 Pro PCs report 62% fewer security incidents and 3 times fewer firmware attacks compared to Windows 10 PCs.
This episode
Discussed as both a key-person risk and a value-creation asset for SpaceX; compared to Warren Buffett by credit analyst Robert Schiffman.
CEO of Eli Lilly since 2017; credited with cutting drug development timelines and transforming Lilly into the world's most valuable healthcare company.
Debuted as a publicly traded company and simultaneously launched its inaugural investment-grade bond offering to fund AI and space infrastructure buildout.
Featured in Bloomberg Big Take; transformed into world's most valuable healthcare company via GLP-1 weight loss drugs Mounjaro and Zepbound under CEO Dave Ricks.
Reported quarterly earnings with a 5% stock drop; cut full-year revenue yield guidance by 100 bps due to Middle East conflict, higher airfare and fuel costs.
Losing key AI talent to Anthropic and OpenAI; described as no longer at the frontier of AI model development; market cap dropped $250B on talent departure news.
Described by Mandeep Singh as the current leader in AI frontier models, surpassing Google and attracting top AI talent away from competitors.
AI coding tool acquired by SpaceX; credited by Mandeep Singh with providing SpaceX's most credible AI use case and preventing a deeper stock decline.
Described as having lost some momentum to Anthropic in AI model development; recruited the OpenClaw co-founder in an attempt to regain position.
Cited as a comparable investment-grade issuer with a longer track record than SpaceX; also has a drug development partnership with Eli Lilly.
Cited as an example of luxury cruise outperformance; stock up 40% year-to-date and doubled over 12 months.
Eli Lilly's brand name for tirzepatide approved for Type 2 diabetes; a key GLP-1 drug driving the company's revenue growth.
Eli Lilly's obesity-indication brand name for tirzepatide; one of the leading GLP-1 weight loss drugs on the market.
Stats
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.